

Prevalence of *qnr* Genes and Antibiotic Susceptibility Patterns among Clinical Isolates of *Klebsiella Pneumoniae* in West of Iran

Mozhgan Azadpour¹, Younes Soleimani², Faranak Rezaie¹, Elnaz Nikanpour³, Hossein Mahmoudvand^{4*} and Sareh jahanbakhsh⁴

¹Razi Herbal Medicine Research Center, Lorestan University of Medical Science, Khorram abad, Iran

²Department of Microbiology, Qom Branch, Islamic Azad University, Qom, Iran

³Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran

⁴Research Center for Tropical and Infectious Diseases, Kerman University of Medical Sciences, Kerman, Iran

*Corresponding author: Hossein Mahmoudvand, Research Center for Tropical and Infectious Diseases, Kerman University of Medical Sciences, Kerman, Iran, Tel: +98-341-2112794; Fax: +98-341-2112794; E-mail: hmahmodvand@yahoo.com

Rec date: April 21, 2014; Acc date: September 22, 2014; Pub date: September 26, 2014

Copyright: © 2014 Azadpour M et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Background: This study aimed to define prevalence of *qnr* genes and antibiotic susceptibility patterns among clinical isolates of *K. pneumoniae* in Lorestan province, west of Iran.

Methods: Totally, 107 *K. pneumoniae* isolates were randomly collected since December until September 2012 from hospitalized patients at general hospitals in Lorestan, Iran. The isolates were from different clinical samples including urine, sputum, etc. Biochemical characterizations were performed for detecting isolates. Antibiotic susceptibility testing by disk diffusion method was performed according to recommendations of Clinical and Laboratory Standards Institute using 12 antibiotic disks. *K. pneumoniae* isolates were screened by multiplex PCR amplification of *qnrA*, *qnrB* and *qnrS* using specific primers and sequence analysis of amplified regions of the isolates was also performed.

Results: 43 (40.2%) out of 107 isolates were multidrug-resistant (MDR). Ciprofloxacin (Quinolone) susceptibility testing showed that 34 isolates were resistant, 7 isolates were intermediately resistant and 66 isolates were sensitive. 18 (16.8%) out of 107 *K. pneumoniae* clinical isolates were positive for *qnr* gene. Among all the *qnr*-positive isolates, 16 isolates (88.9%) carried *qnrB*, 1 isolate (5.55%) carried *qnrS* and the rest (5.55%) carried both *qnrB* and *qnrS* genes while no *qnrA* was detected in these clinical isolates. *qnr* determinants were detected in 8 (23.5%) of the ciprofloxacin-resistant isolates as well as 1 (14.3%) and 9 (13.6%) intermediate and sensitive isolates, respectively. No significant association was observed between ciprofloxacin resistance and presence of *qnr* genes ($P > 0.05$).

Conclusion: Findings of the present study indicated that emergence of *qnr* determinants contributed to development and spread of quinolone resistance in Iranian isolates of *K. pneumoniae*.

Keywords: *Klebsiella pneumoniae*, *qnr* gene, Quinolone resistance, Lorestan, Iran

Introduction

Klebsiella pneumoniae (family Enterobacteriaceae) is an opportunistic pathogen that usually causes hospital and community acquired bacterial infections in humans [1]. In recent years, emergence of multidrug-resistant *K. pneumoniae* isolates has become a serious antibiotic management problem and led to great concern around the world [1,2]. At present, quinolone resistance is a widespread phenomenon among the Enterobacteriaceae [2,3]. Main mechanisms of resistance to quinolones in this family including mutations in the quinolone resistance determining regions (QRDRs) of DNA gyrase and topoisomerase IV, efflux pumps enhancement or decreased accumulation mediated by reduce in permeability of bacterial cell wall are chromosomally mediated [4-8]. Recently, mechanisms of plasmid-mediated quinolones resistance (PMQR) by *qnr* genes have been reported [9] These *qnr* genes (*qnrA*, *qnrB* and *qnrS*) encode proteins of the pentapeptide repeat family that interfere with the action of

quinolones on bacterial DNA gyrase and topoisomerase IV [9-11]. Although the *qnr* gene indicates a low level of resistance to quinolones, its attendance aids the selection of chromosomal mutations, facilitating increased resistance in the host strain [9-11]. Frequency of *qnr* genes PMQR associated with the *qnr* genes in different human clinical enterobacterial isolates was determined first in the USA in 1994 using a *K. pneumoniae* isolate (later termed *qnrA1*) [9], which was then widely reported worldwide [12-19]. However, no study has been done on prevalence of *qnr* genes among enterobacterial clinical isolates in Iran. For the first time, this study aimed to define prevalence of *qnr* genes and antibiotic susceptibility patterns among clinical isolates of *K. pneumoniae* from general hospitals in Lorestan province, west of Iran.

Materials and Methods

Studied area

This descriptive study was carried out since December until September 2012 on hospitalized patients at general hospitals of Lorestan province, located between valleys of Zagros Mountain in west of Iran and bordering with provinces of Markazi, Hamedan, Kermanshah, Khuzestan, Ilam and Isfahan. Lorestan covers an area of 28.294 km² and its population is approximately 2 million people. Major cities of this province are Khorramabad, Borujerd, Aligoodarz, Dorood, Koohdasht, Azna, Alashtar, Noorabad and Pol-e-Dokhtar (Figure 1) [20].




Figure 1: Geographical locations where this study was carried out

Bacterial isolates

Totally, 107 *K. pneumoniae* isolates were randomly collected since December until September 2012 from hospitalized patients at general hospitals of Lorestan, Iran. The isolates were collected from different specimens, including urine, sputum, lesion, blood and other specimens. All the isolates were routinely cultured on Mueller-Hinton (MH) agar plates and typical colonies were picked up and identified by biochemical tests using the API®-20E test kits (bioMérieux, Lyon, France). The bacteria were grown at 37°C for 18–24 h in order to prepare bacterial suspension and DNA extraction.

Susceptibility testing

Antibiotic susceptibility of the isolates to amikacin (10 µg), ampicillin (10 µg), meropenem (10 µg), nalidixic acid (30 µg), cefotaxime (30 µg), ceftazidime (30 µg), cefterixone (30 µg), cephalexine, ciprofloxacin (5 µg), cefexim (30 µg), gentamicin (10 µg) and imipenem (10 µg) (all the antibiotics were purchased from Oxoid, UK) was determined by disk diffusion method as recommended by Clinical and Laboratory Standards Institute (CLSI) [21] on Mueller-Hinton agar plates. In addition, *K. pneumoniae* ATCC BAA-1705 was used as a quality control strain.

Screening for *qnr* genes

The 107 clinical isolates of *K. pneumoniae* were screened by multiplex PCR amplification of *qnrA*, *qnrB* and *qnrS* using specific primers shown in Table 1, as previously described by Robicsek et al. [3]. Briefly, the colonies were transferred to an Eppendorf tube filled with water and boiled to prepare DNA templates for PCR. Target

fragments were amplified under PCR conditions of 94°C for 45 s, 53°C for 45 s and 72°C for 60 s with cycle number of 32. Positive (containing strains with known *qnr* genes) and negative (without DNA template) controls were included in each run. Amplification products were provisionally identified according to their sizes in ethidium bromide-stained agarose gels.

Amplicon	Primers	Sequence (5'–3')	Size (bp)
<i>QnrA</i>	<i>qnrA-A</i> <i>qnrA-B</i>	ATTTCTCACGCCAGGATTG GATCGGCAAAGGTTAGGTCA	516
<i>QnrB</i>	<i>qnrB-A</i> <i>qnrB-B</i>	GATCGTGAAAGCCAGAAAGG ACGATGCCTGGTAGTTGTCC	469
<i>QnrS</i>	<i>qnrS-A</i> <i>qnrS-B</i>	ACGACATTGTCAACTGCAA TAAATTGGCACCCCTGTAGGC	417

Table 1: Sequences of primers used for multiplex PCR

DNA sequencing

DNA sequence analysis was performed using direct sequencing of both strands using an auto-sequencer. The obtained DNA sequences were compared and analyzed using BLAST online search engine from GenBank in website of National Center for Biotechnology Information (<http://www.ncbi.nlm.nih.gov/blast>).

Statistical analysis

Data analysis was carried out using SPSS statistical package (version 17.0) (SPSS Inc., Chicago, IL, USA). P value of <0.05 was considered statistically significant.

Results

Out of 107 isolates, 43 isolates (40.2%) were multidrug-resistant (MDR). The highest rate of resistance was observed in ceftazidime and cefotaxime. Moreover, the lowest rate of resistance was seen in imipenem, meropenem and amikacin, respectively. Ciprofloxacin (Quinolone) susceptibility testing showed that 34 isolates (31.8%) were resistant, 7 isolates (6.5%) were intermediately resistant and 66 isolates (61.7%) were sensitive. 18 (16.8%) out of 107 *K. pneumoniae* clinical isolates screened by multiplex PCR, were positive for the *qnr* gene. Among all the *qnr*-positive isolates, 16 isolates (88.9%) carried *qnrB*, 1 isolate (5.55%) carried *qnrS* and the rest (5.55%) carried both *qnrB* and *qnrS* genes while no *qnrA* was detected in the present clinical isolates. Table 2 shows clinical characteristics of these isolates and distribution of *qnrA*, *qnrB* and *qnrS*. *Qnr* determinants were detected in 8 (23.5%) of the ciprofloxacin-resistant isolates as well as 1 (14.3%) and 9 (13.6%) intermediate and sensitive isolates, respectively (Table 3). No significant association was found between ciprofloxacin resistance and presence of *qnr* genes ($P=0.074$). Moreover, complete sequences of positive *qnrB* and *qnrS* isolates were submitted to the GenBank database and assigned accession numbers AB894351, AB894352, AB894353 and AB894354.

Discussion

Klebsiella pneumoniae colonizes >75% of hospitalized patients and causes the estimated 8% of all nosocomial infections including pneumonia, urinary tract, wound and diarrhoea infections [22]. At

present, emergence of multidrug-resistant *K. pneumoniae* isolates have become a serious antibiotic management problem and led to great concern worldwide [1,2]. This investigation provided the first epidemiological survey on the frequency of *qnrA*, *qnrB* and *qnrS* genes by multiplex PCR in Lorestan province, Iran, between December and September 2012. In this survey, *qnr* genes were determined in 18 (16.8%) of the isolates. This rate of *qnr* prevalence was consistent with some studies carried out in Taiwan and the USA (15, 16). Prevalence of *qnr* in the present study was also higher than that shown in other areas in Brazil (2.3%), Singapore (5.2%) and the USA (11.1%) [12,13,17]. In contrast, it was much lower than the prevalence of *qnr* genes detected in Malaysia (48.9%) and China (65.5%) [14,19].

Number of Strains	Specimen	Sex	Age	Diagnoses	<i>Qnr</i>
Kp6	Sputum	Male	12 Months	Pneumonia	<i>qnrB</i>
Kp 8	Urine	Male	6 years	UTI ^a	<i>qnrB</i>
Kp13	Sputum	Female	23 years	Pneumonia	<i>qnrB</i>
Kp17	Urine	Female	9 years	UTI ^a	<i>qnrS</i>
Kp18	Sputum	Male	3 years	Pneumonia	<i>qnrB</i>
Kp19	Tracheal	Male	51 years	Pneumonia	<i>qnrB</i>
Kp26	Sputum	Male	13 years	Pneumonia	<i>qnrB</i>
Kp33	Sputum	Female	6 Months	Pneumonia	<i>qnrB</i>
Kp42	Urine	Female	33 years	UTI ^a	<i>qnrB</i>
Kp44	Sputum	Male	14 Months	Pneumonia	<i>qnrB</i>
Kp57	Urine	Female	52 years	UTI ^a	<i>qnrB</i>
Kp68	Sputum	Female	12 Months	Pneumonia	<i>qnrB</i>
Kp73	Urine	Male	4 years	UTI ^a	<i>qnrB</i>
Kp84	Sputum	Female	8 Months	Pneumonia	<i>qnrB</i> , <i>qnrS</i>
Kp93	Sputum	Male	2 years	Pneumonia	<i>qnrB</i>
Kp97	Urine	Male	19 Months	UTI ^a	<i>qnrB</i>
Kp101	Sputum	Female	11 years	Pneumonia	<i>qnrB</i>
Kp104	Sputum	Male	47 years	Pneumonia	<i>qnrB</i>

Table 2: Clinical characteristics and *qnr* genotype of the *qnr*-positive isolates. a :Urinary tract infection

Ciprofloxacin susceptibility	No. (%) isolate with <i>qnr</i> determinants				
	<i>qnrA</i>	<i>qnrB</i>	<i>qnrS</i>	<i>qnrB</i> + <i>qnrS</i>	Total
Sensitive (n=66)	0 (0)	8 (12.1)	0 (0)	1 (1.5)	9 (13.6)
Intermediate (n=7)	0 (0)	1 (16.6)	0 (0)	0 (0)	1 (14.3)

Resistant (n=34)	0 (0)	7 (20.6)	1 (2.9)	0 (0)	8 (23.5)
Total (n=107)	0 (0)	16 (14.9)	1 (0.93)	1 (0.93)	18(16.8)

Table 3: Frequency of *qnr* genes based on ciprofloxacin (Quinolone) susceptibility in *K. pneumoniae* isolates from Lorestan, Iran

The present findings indicated that *qnrB* was the most prevalent one (88.9%), followed by *qnrS* (5.55%), whereas no isolates carried *qnrA* among all the clinical isolates. In the studies conducted by Minarini et al. [13] and Saiful et al. [19] on clinical isolates in Brazil (2.3%) and Malaysia (31.9%), respectively, *qnrB* has been proven to be more prevalent than other *qnr* genes among the tested clinical isolates. In contrast, in other investigations carried out in China and the USA, it has been shown that *qnrS* (14.9%) and *qnrA* (14%) are the most prevalent of all *K. pneumoniae* clinical isolates screened by multiplex PCR, respectively [16,18]. The present investigation shows no *qnrA* in its clinical isolates; similarly, Minarini et al. [13] and Saiful et al. [19] in Brazil and Malaysia have indicated no *qnrA* or *qnrS*-positive isolates among their clinical isolates of *K. pneumoniae*, respectively.

In the present study, *qnr* determinants (*qnrA*, *qnrB* and *qnrS*) were identified from 8 (23.5%) ciprofloxacin-resistant, 1 (14.3%) intermediate and 9 (13.6%) sensitive isolates. Similar to these results, Saiful et al. [19] reported that the highest percentage of *qnr* determinants (47.8%) was found in ciprofloxacin-resistant isolates. It has been previously demonstrated that clinical isolates with *qnr* determinants are known to harbor multiple ciprofloxacin resistance mechanisms such as variations in *gyrA* or reduce the drug permeability and therefore facilitate high resistance to ciprofloxacin [9,10]. In this survey, it was also proven due to lack of significant association between ciprofloxacin resistance and presence of *qnr* determinants. Moreover, the results reflected considerable frequency of *qnr*-positive *K. pneumoniae* among clinical isolates in Iran. This frequency of *qnr* genes indicated that *qnr* genes were disseminating and subsequently prevalence of MDR *K. pneumoniae* was increasing because of probable increasing resistance to quinolone.

Conclusion

The findings of our study showed considerable frequency of *qnr*-positive *K. pneumoniae* among clinical isolates in Iran. Therefore, it is necessary to properly use antibiotics, especially quinolone antibiotics, and continuously monitor resistance patterns in *K. pneumoniae* in hospital settings.

Acknowledgements

This study was supported by *Research Center for Tropical and Infectious Diseases, Kerman University of Medical Sciences, Kerman, Iran*. We would like to thank *Dr. Farnaz Kheirandish* and *Dr. Hossein Hosseini Naveh* for data analysis and data collection.

References

- Ko WC, Paterson DL, Sagnimeni AJ, Hansen DS, Von Gottberg A, et al. (2002) Community-acquired *Klebsiella pneumoniae* bacteremia: global differences in clinical patterns. *Emerg Infect Dis* 8: 160-166.
- Strahilevitz J, Jacoby GA, Hooper DC, Robicsek A (2009) Plasmid-mediated quinolone resistance: a multifaceted threat. *Clin Microbiol Rev* 22: 664-689.

3. Robicsek A, Jacoby GA, Hooper DC (2006) The worldwide emergence of plasmid-mediated quinolone resistance. *Lancet Infect Dis* 6: 629-640.
4. Yoshida H, Bogaki M, Nakamura M, Nakamura S (1990) Quinolone resistance-determining region in the DNA gyrase *gyrA* gene of *Escherichia coli*. *Antimicrob Agents Chemother* 34: 1271-1272.
5. Poole K (2005) Efflux-mediated antimicrobial resistance. *J Antimicrob Chemother* 56: 20-51.
6. Hooper DC (1998) Bacterial topoisomerases, anti-topoisomerases, and anti-topoisomerase resistance. *Clin Infect Dis* 27 Suppl 1: S54-63.
7. Hooper DC (2003) Mechanisms of quinolone resistance. Hooper D, Rubinstein E (Eds.) *Quinolone Antimicrobial Agents*, ASM Press, Washington, DC.
8. Nikaido H (2003) Molecular basis of bacterial outer membrane permeability revisited. *Microbiol Mol Biol Rev* 67: 593-656.
9. Martínez-Martínez L, Pascual A, Jacoby GA (1998) Quinolone resistance from a transferable plasmid. *Lancet* 351: 797-799.
10. Tran JH, Jacoby GA, Hooper DC (2005) Interaction of the plasmid-encoded quinolone resistance protein Qnr with *Escherichia coli* DNA gyrase. *Antimicrob Agents Chemother* 49: 118-125.
11. Jacoby GA, Walsh KE, Mills DM, Walker VJ, Oh H, et al. (2006) *qnrB*, another plasmid-mediated gene for quinolone resistance. *Antimicrob Agents Chemother* 50: 1178-1182.
12. Wang M, Sahn DF, Jacoby GA, Hooper DC (2004). Emerging plasmid-mediated quinolone resistance associated with the *qnr* gene in *Klebsiella pneumoniae* clinical isolates in the United States. *Antimicrob Agent Chemother* 48: 1295-9.
13. Minarini LA, Poirel L, Cattoir V, Darini AL, Nordmann P (2008). Plasmid-mediated quinolone resistance determinants among enterobacterial isolates from outpatients in Brazil. *J Antimicrob Chemother* 62: 474-78.
14. Yang H, Chen H, Yang Q, Chen M, Wang H (2008) High prevalence of plasmid-mediated quinolone resistance genes *qnr* and *aac(6)-Ib-cr* in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. *Antimicrob Agents Chemother* 52: 4268-4273.
15. Wu JJ, Ko WC, Tsai SH, Yan JJ (2007). Prevalence of plasmid-mediated quinolone resistance determinants *qnrA*, *qnrB* and *qnrS* among clinical isolates of *Enterobacter cloacae* in a Taiwanese Hospital. *Antimicrob Agent Chemother*; 51:1223-7.
16. Robicsek A, Strahilevitz J, Sahn DF, Jacoby GA, Hooper DC (2006) *qnr* prevalence in ceftazidime-resistant Enterobacteriaceae isolates from the United States. *Antimicrob Agents Chemother* 50: 2872-2874.
17. Teo JW, Ng KY, Lin RT (2009) Detection and genetic characterisation of *qnrB* in hospital isolates of *Klebsiella pneumoniae* in Singapore. *Int J Antimicrob Agents* 33: 177-180.
18. Wang A, Yang Y, Lu Q, Wang Y, Chen Y, et al. (2008) Presence of *qnr* gene in *Escherichia coli* and *Klebsiella pneumoniae* resistant to ciprofloxacin isolated from pediatric patients in China. *BMC Infect Dis* 8: 68.
19. Saiful Anuar AS, Mohd Yusof MY, Tay ST (2013) Prevalence of plasmid-mediated *qnr* determinants and gyrase alteration in *Klebsiella pneumoniae* isolated from a university teaching hospital in Malaysia. *Eur Rev Med Pharmacol Sci* 17: 1744-1747.
20. Kheirandish F, Sharafi AC, Kazemi B, Bandehpour M, Tarahi Mj, et al. (2013) First molecular identification of *Leishmania* species in a new endemic area of cutaneous leishmaniasis in Lorestan, Iran. *Asian Pac J Trop Med* 6: 713-717.
21. Pereira V, Lopes C, Castro A, Silva J, Gibbs P, et al. (2009) Characterization for enterotoxin production, virulence factors, and antibiotic susceptibility of *Staphylococcus aureus* isolates from various foods in Portugal. *Food Microbiol* 26: 278-282.
22. Podschun R, Ullmann U (1998) *Klebsiella* spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors. *Clin Microbiol Rev* 11: 589-603.